Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

(OSKIRA-3): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With Inadequate Response to a TNF-alpha Antagonist

NCT01197755 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01197755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01197755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
(OSKIRA-3): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With Inadequate Response to a TNF-alpha Antagonist
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2010
Completion date
February 28, 2013
Enrollment
323 (actual)
Sites
135

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis